Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Gamida Cell Ltd is a biotechnology business based in the US. Gamida Cell shares (GMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Gamida Cell employs 166 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.77 |
|---|---|
| 52-week range | $1.79 - $6.84 |
| 50-day moving average | $2.38 |
| 200-day moving average | $3.17 |
| Wall St. target price | $14.40 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.53 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.77 from 2022-06-30
| 1 week (2022-06-22) | -7.33% |
|---|---|
| 1 month (2022-06-01) | -18.06% |
| 3 months (2022-04-01) | -56.19% |
| 6 months (2021-12-31) | -30.31% |
| 1 year (2021-07-01) | -72.52% |
|---|---|
| 2 years (2020-07-01) | -61.01% |
| 3 years (2019-07-01) | 5.09 |
| 5 years (2017-06-27) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -33.05% |
| Return on equity TTM | -166.84% |
| Profit margin | 0% |
| Book value | $0.42 |
| Market capitalisation | $118.1 million |
TTM: trailing 12 months
We're not expecting Gamida Cell to pay a dividend over the next 12 months.
Over the last 12 months, Gamida Cell's shares have ranged in value from as little as $1.79 up to $6.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gamida Cell's is 1.8195. This would suggest that Gamida Cell's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Gamida Cell Ltd. , a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.